MAR 2 4 2004 W

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Tetsuo NAGANO et al.

Group Art Unit: 1743

Appln. No.: 10/744,007

Examiner: Unknown

Filed: December 24, 2003

For : DIAMINORHODAMINE DERIVATIVE

## INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with Applicants' duty of disclosure under 37 C.F.R. 1.56, Applicants hereby submit the following Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98, and in conformance with MPEP 609 and 37 C.F.R. 1.98(d).

Applicants hereby make of record the disclosure statement filed August 20, 2001, and the Information cited by the Examiner in the Office Action mailed February 4, 2003 in parent Application No. 09/641,350.

The Examiner is respectfully requested to consider the documents cited in the parent application, and to make the documents cited therein of record in the instant application.

Applicants note that copies of documents cited in the above-mentioned disclosure statement have been submitted in parent Application No. 09/641,350. Accordingly, pursuant to 37 C.F.R. 1.98(d) copies of the documents are not being submitted herewith, and the Examiner is invited to review and consider the documents in the parent application. Of course, should any of the

P24350.A01

documents not be readily available to the Examiner, the Examiner is requested to contact the undersigned and additional copies will be submitted.

For the convenience of the Examiner, the above-noted documents cited in the parent applications are listed on the attached Forms PTO-1449. The Examiner is requested to initial the Forms PTO-1449, and to return the initialed copy with the next communication from the U.S. Patent and Trademark Office.

Should the Examiner have any questions or comments regarding this matter, the undersigned may be contacted at the below-listed telephone number.

Respectfully/submitted,

Tetsuo MAGANO et al.

Bruce H. Bernstein

Agno 33,04

Reg. No. 29,027

March 24, 2004 GREENBLUM & BERNSTEIN, P.L.C. 1950 Roland Clarke Place Reston, VA 20191

(703) 716-1191

P24350.P04

Form PTO-1449

U.S. Department of Commerce Patent and Trademark Office

Atty. Docket No.

P24350

Serial No. 10/744,007

RADEMARK OTHEC					mark Office	10/744,007									
INFORMATION DISCLOSURE STATEMENT BY APPLICANT							ICA	NT		ΙΤ	Applicant Tetsuo NAGANO et al.				
(Use several sheets if necessary)									essary)		Filing Date December 24, 2003		Group 1743		
										U.S. PATENT	DOCUMENTS				
EXAMINER INITIAL		N		DOC IBER		IEN	Т		DATE	NAME CLASS		CLASS	SUBCLASS FILING DATE IF APPROPRIATE		
-		5	8	7	4	5	9	0	02/23/99	NAGANO et a	l.				
		6	2	0	1	1	3	4	03/2001	NAGANO et a	<b>i.</b>			<u>.</u>	
		6	4	6	9	0	0 5 I 10/2002 NAGANO et al.								
									F	OREIGN PATE	ENT DOCUMENTS	8			
			DOCUMENT NUMBER				DATE	COUNTRY CI		CLASS	SUBCLASS	TRANSLATION YES NO			
	9	-	0	4	3	1	5	3	02/14/97	JAPAN					
	1	0	2	2	6	6	8	8	08/25/98	JAPAN					
	9	9	/	0	1	4	4	7	01/14/99	W.I.P.O.		····			
	0	1	/	6	3	2	6	5	08/2001	W.I.P.O.					
						o	THI	ER I	OCUMEN	TS (Including A	uthor, Title, Date, l	Pertinent Pages	, Etc.)		
		1	E	ingli	sh L	ang	guag	e A	bstract of J	P 9-043153					
		2	2 English Language Abstract of JP 10-226688									-			
		3	Chemistry Today [Gendai Kagaku], April, pp. 25-29 (1994).									. "			
		4	PALMER et al., <u>Nature</u> , Vol. 327, pp. 524-526 (1987).												
		5	KELM et al., Circulation Research, Vol. 66, No. 6, pp. 1561-1575 (1990).												
		6	SHIBUKI, Neuroscience Research 9, pp. 69-76 (1990).												
		7	MALINSKI et al., <u>Nature</u> , Vol. 358, pp. 676-678 (1992).												
		8	GREEN et al., Analytical Biochemistry, Vol. 126, pp. 131-138 (1982).												
		9	çc	App	roac	hes	Fro	m T	The Newest	Medicine [Sais	hin Igaku Kara No	Approach] 12	2, NO", Ed. by N	loboru Tod	a, pp. 42-52.
	1	0	ARCHER, <u>The FASEB Journal</u> , Vol.7, pp. 349-360 (1993).												
	1	1	STAINTON, Analytical Chemistry, Vol. 46, No. 11, p. 1616, (1974.												
	1	2	SAWICKI et al., Microchemical Journal, Vol. 16, pp. 657-672 (1971).												
	1	3	WIERSMA, Analytical Letters, Vol. 3, No. 3, pp. 123-132 (1970).												
	1	4	C	AM	IAN	νI, <u>]</u>	Γala	nta,	Vol. 33, N	o. 8, pp. 649-65	52 (1986).				
EXAMINER											DATE CONSIDE	ERED	. <u> </u>		

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

P24350.P04

Form	pT	∩_ി	1449

U.S. Department of Commerce Patent and Trademark Office

Serial No. 10/744,007

RADEMAR INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant Tetsuo NAGANO et al.

Atty. Docket No.

Filing Date

P24350

Group

				December 24, 2003	1743					
			OTHER DOCUMENTS (Including Aut	hor, Title, Date, Pertinent Pages, l	Etc.)					
1		5	MISKO, Analytical Biochemistry, 214, pp. 11-16 (1993).							
1	(	5	DOJIN News, No. 74, p. 18 (1995).							
1		7	SAWICKI, <u>Analytical Letters</u> , 4, (11), pp. 761-775 (1971).							
1		8	MAEDA et al., <u>Journal of Leukocyte Biology</u> , Vol. 56, pp. 588-592 (1994.)							
1	9	9	AKAIKE et al., <u>Biochemistry</u> , Vol. 32, pp. 827-832 (1993).							
2	! (	0	Tokyo Chemical Industry Co., Ltd., Organic Chemicals Catalog, 32, (1994).							
2	!	1	KIKUCHI et al., Biol. Pharm. Bull., 19, (4), p	KIKUCHI et al., <u>Biol. Pharm. Bull.</u> , 19, (4), pp. 649-651 (1996).						
2	! 2	2	FLEMING et al., Circulation Research, Vol. 7	4, No. 6 pp. 1220-1226 (1994).						
2	2 3	3	Abstracts of Papers, Part 1, 218th ACS Nation	al Meeting, American Chemical	Society, August 22-26 (1999).					
2	! 4	4	KOJIMA et al., Angew Chem. Int. Ed., 38, No. 21 pp. 3209-3212 (1999).							
2	: :	5	KOJIMA et al., <u>Tetrahedron Letters</u> , 41, pp. 6	9-72 (2000).						
2	: (	5	Analytical Chemistry. "Bioimaging of Nitric C	Oxide with Fluorescent Indicators	s Based on the Rhodamine					
			Chromophore". KOJIMA et al March 2001.							
	$\perp$			,						
	$\perp$	$\downarrow$								
	_									
	_	4								
	_	4	<u> </u>							
	_	4	·		741					
	+	4								
	+	+		·						
	+	+		·						
	+	$\dashv$								
	+	$\dashv$	.,		<u> </u>					
	+	$\dashv$			· · · · · · · · · · · · · · · · · · ·					
	+	$\dashv$	17.,.	· · · · · · · · · · · · · · · · · · ·						
EXAMINER				DATE CONSIDERED	· · · · · · · · · · · · · · · · · ·					

<sup>\*</sup>EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.